



Clinical trial results:

A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed by a 12-Week Extension Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in Subjects with Mild to Moderate Ulcerative Colitis.

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2012-003974-18 |
| Trial protocol | HU BG |
| Global end of trial date | 28 November 2014 |

Results information

| | |
|--------------------------------|--------------|
| Result version number | v1 (current) |
| This version publication date | 29 July 2016 |
| First version publication date | 29 July 2016 |

Trial information

Trial identification

| | |
|-----------------------|------------|
| Sponsor protocol code | VB-201-064 |
|-----------------------|------------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Vascular Biogenics Ltd. |
| Sponsor organisation address | 6 Jonathan Netanyahu St., Or Yehuda, Israel, 60376 |
| Public contact | VBL, Vascular Biogenics Ltd., 972 36346450, |
| Scientific contact | VBL, Vascular Biogenics Ltd., 972 36346450, |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 02 February 2016 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 28 November 2014 |
| Global end of trial reached? | Yes |
| Global end of trial date | 28 November 2014 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

- Safety Objective

- To examine the safety and tolerability of up to 24 weeks' treatment with VB-201 or placebo in subjects with Ulcerative Colitis

- Efficacy Objective

- Base Phase: To examine the effect of treatment with VB-201 80 mg twice daily, compared to placebo (initial 12 weeks) on measures of disease activity in subjects with Ulcerative Colitis.

- Extension Phase: To examine the effect of longer-term treatment with VB-201 (24 weeks) on measures of disease activity in subjects with Ulcerative Colitis.

Protection of trial subjects:

The trial was conducted in accordance with applicable national and international laws and regulations, the ICH-GCP guideline and the ethics principles that have their origins in the Declaration of Helsinki

Background therapy:

Not applicable

Evidence for comparator:

Not applicable

| | |
|---|------------------|
| Actual start date of recruitment | 30 November 2012 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------|
| Country: Number of subjects enrolled | Bulgaria: 23 |
| Country: Number of subjects enrolled | Hungary: 1 |
| Country: Number of subjects enrolled | Poland: 88 |
| Worldwide total number of subjects | 112 |
| EEA total number of subjects | 112 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 | 0 |

| | |
|---------------------------|-----|
| months) | |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 107 |
| From 65 to 84 years | 5 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

The first informed consent was given on 22 January 2013 and last patient last visit was on 28 November 2014.

Pre-assignment

Screening details:

Male or female subjects, ≥ 18 years of age, who had a diagnosis of active Ulcerative Colitis for at least 6 months prior to screening were selected according to the protocol inclusion and exclusion criteria.

Period 1

| | |
|------------------------------|-------------------------------------|
| Period 1 title | Period 1 (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Data analyst |

Blinding implementation details:

The identity of the treatments was concealed by the use of trial medications that were all identical in packaging, labelling and schedule of administration. A combined batch number was generated. The IMP and the respective vehicle were indistinguishable in appearance, consistency and odor.

Arms

| | |
|------------------------------|----------------|
| Are arms mutually exclusive? | Yes |
| Arm title | VB-201 (Arm A) |

Arm description:

The VB-201 dose was 80 mg/day for the initial 2 weeks followed by 80 mg BID (160 mg/day) for 10 weeks.

After the initial 12 weeks, subjects entered the Extension Phase. During this phase, subjects continued dosing VB-201 at 80 mg BID.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | VB-201 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Capsule |
| Routes of administration | Oral use |

Dosage and administration details:

All doses of trial medication were taken approximately 12 hours apart with food.

| | |
|------------------|--------------------------|
| Arm title | Placebo & VB-201 (Arm B) |
|------------------|--------------------------|

Arm description:

Subjects received placebo for weeks 1-12, followed by extension phase where subjects switched to dosing with VB-201 dosed at 80 mg/day for the initial 2 weeks followed by 80 mg BID during the final 10 weeks of the trial.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | VB-201 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Capsule |
| Routes of administration | Oral use |

Dosage and administration details:

All doses of trial medication (placebo or VB-201) were taken approximately 12 hours apart with food.

| | |
|--|----------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Capsule |
| Routes of administration | Oral use |

Dosage and administration details:

All doses of trial medication (placebo or VB-201) were taken approximately 12 hours apart with food..

| Number of subjects in period 1 | VB-201 (Arm A) | Placebo & VB-201 (Arm B) |
|---------------------------------------|----------------|--------------------------|
| Started | 58 | 54 |
| Completed | 42 | 46 |
| Not completed | 16 | 8 |
| Disease progression | 1 | - |
| Adverse event, non-fatal | 6 | 3 |
| Medical monitor decision | - | 1 |
| Lost to follow-up | 1 | - |
| Lack of cooperation | - | 1 |
| Lack of efficacy | 5 | 1 |
| Lack of motivation | 3 | 1 |
| Protocol deviation | - | 1 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|----------------|
| Reporting group title | VB-201 (Arm A) |
|-----------------------|----------------|

Reporting group description:

The VB-201 dose was 80 mg/day for the initial 2 weeks followed by 80 mg BID (160 mg/day) for 10 weeks.

After the initial 12 weeks, subjects entered the Extension Phase. During this phase, subjects continued dosing VB-201 at 80 mg BID.

| | |
|-----------------------|--------------------------|
| Reporting group title | Placebo & VB-201 (Arm B) |
|-----------------------|--------------------------|

Reporting group description:

Subjects received placebo for weeks 1-12, followed by extension phase where subjects switched to dosing with VB-201 dosed at 80 mg/day for the initial 2 weeks followed by 80 mg BID during the final 10 weeks of the trial.

| Reporting group values | VB-201 (Arm A) | Placebo & VB-201 (Arm B) | Total |
|------------------------------------|----------------|--------------------------|-------|
| Number of subjects | 58 | 54 | 112 |
| Age categorical Units: Subjects | | | |

| | | | |
|--|------------------|------------------|----------|
| Age continuous Units: years arithmetic mean standard deviation | 39.57 ± 15.15 | 40.54 ± 13.05 | - |
| Gender categorical Units: Subjects Female Male | 23 35 | 21 33 | 44 68 |
| Full modified Mayo Score Units: not applicable arithmetic mean standard deviation | 8 ± 1.4 | 7.83 ± 1.58 | - |

End points

End points reporting groups

| | |
|---|--------------------------|
| Reporting group title | VB-201 (Arm A) |
| Reporting group description: The VB-201 dose was 80 mg/day for the initial 2 weeks followed by 80 mg BID (160 mg/day) for 10 weeks. After the initial 12 weeks, subjects entered the Extension Phase. During this phase, subjects continued dosing VB-201 at 80 mg BID. | |
| Reporting group title | Placebo & VB-201 (Arm B) |
| Reporting group description: Subjects received placebo for weeks 1-12, followed by extension phase where subjects switched to dosing with VB-201 dosed at 80 mg/day for the initial 2 weeks followed by 80 mg BID during the final 10 weeks of the trial. | |

Primary: Remission Rates

| | |
|---|-----------------|
| End point title | Remission Rates |
| End point description: | |
| End point type | Primary |
| End point timeframe: | |
| Summary of remission rates by visit and treatment group, base and extension phase | |

| End point values | VB-201 (Arm A) | Placebo & VB-201 (Arm B) | | |
|-----------------------------|-----------------|--------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 57 | 53 | | |
| Units: number of subjects | | | | |
| remission at week 12 | 6 | 8 | | |
| no remission at week 12 | 51 | 45 | | |
| remission at week 24 | 13 | 10 | | |
| no remission at week 24 | 44 | 43 | | |

Statistical analyses

| | |
|-----------------------------------|---|
| Statistical analysis title | Remission at week 12 base phase |
| Statistical analysis description: | |
| P-value chi-square test | |
| Comparison groups | VB-201 (Arm A) v Placebo & VB-201 (Arm B) |

| | |
|---|---------------|
| Number of subjects included in analysis | 110 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.4726 |
| Method | Chi-squared |

| | |
|-----------------------------------|----------------------|
| Statistical analysis title | Remission at week 24 |
|-----------------------------------|----------------------|

Statistical analysis description:

Between group comparison week 12 Placebo (weeks 0-12) vs week 24 VB-201 80mg twice daily (weeks 0-24)

| | |
|---|---|
| Comparison groups | VB-201 (Arm A) v Placebo & VB-201 (Arm B) |
| Number of subjects included in analysis | 110 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.3038 |
| Method | Chi-squared |

Primary: Safety

| | |
|-----------------|-----------------------|
| End point title | Safety ^[1] |
|-----------------|-----------------------|

End point description:

Summary of incidence of treatment emergent adverse events (TEAEs) for the study, for subjects in treatment Arms A& B. A full breakdown of adverse events (AEs) by study group and treatment administered (VB-201, placebo) is presented in the 'adverse events' section.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Entire duration of the study

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As safety is specified as a primary endpoint, descriptive statistics only are reported.

| End point values | VB-201 (Arm A) | Placebo & VB-201 (Arm B) | | |
|---|-----------------|--------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 58 | 54 | | |
| Units: number of subjects | | | | |
| Subjects with any AEs | 35 | 27 | | |
| Subjects with any Serious Adverse Events (SAEs) | 5 | 6 | | |
| Subjects with any AEs leading to withdrawal | 7 | 4 | | |
| Subjects with at least one Mild TEAE | 29 | 13 | | |
| Subjects with at least one Moderate TEAE | 11 | 17 | | |
| Subjects with at least one Severe TEAE | 4 | 3 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Secondary Efficacy

| | |
|-----------------|--------------------|
| End point title | Secondary Efficacy |
|-----------------|--------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

weeks 0-24 Arm A & weeks 12-24 Arm B.

| End point values | VB-201 (Arm A) | Placebo & VB-201 (Arm B) | | |
|--------------------------------------|-----------------|--------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 57 | 53 | | |
| Units: Total Modified Mayo score | | | | |
| arithmetic mean (standard deviation) | | | | |
| Week 12 | 6.33 (± 2.61) | 5.64 (± 2.78) | | |
| Week 24 | 5.58 (± 3.17) | 4.57 (± 2.71) | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Throughout the duration of the study (from screening visit to follow-up visit)

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 15.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|----------------|
| Reporting group title | VB-201 (Arm A) |
|-----------------------|----------------|

Reporting group description:

The VB-201 dose was 80 mg/day for the initial 2 weeks followed by 80 mg BID (160 mg/day) for 10 weeks.

After the initial 12 weeks, subjects entered the Extension Phase. During this phase, subjects continued dosing VB-201 at 80 mg twice daily..

| | |
|-----------------------|--------------------------|
| Reporting group title | placebo & VB-201 (Arm B) |
|-----------------------|--------------------------|

Reporting group description:

Subjects received placebo for weeks 1-12, followed by extension phase where subjects switched to dosing with VB-201 dosed at 80 mg/day for the initial 2 weeks followed by 80 mg twice daily during the final 10 weeks of the trial.

| Serious adverse events | VB-201 (Arm A) | placebo & VB-201 (Arm B) | |
|---|----------------|--------------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 5 / 58 (8.62%) | 6 / 54 (11.11%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Surgical and medical procedures | | | |
| Ovarian cystectomy | | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |

| | | | |
|---|----------------|----------------|--|
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colitis ulcerative | | | |
| subjects affected / exposed | 4 / 58 (6.90%) | 3 / 54 (5.56%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Bronchopneumonia | | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | VB-201 (Arm A) | placebo & VB-201 (Arm B) | |
|---|------------------|--------------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 33 / 58 (56.90%) | 24 / 54 (44.44%) | |
| Surgical and medical procedures | | | |
| Tooth extraction | | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) | |
| occurrences (all) | 0 | 1 | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| Mucosal haemorrhage | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Pyrexia | | | |
| subjects affected / exposed | 2 / 58 (3.45%) | 1 / 54 (1.85%) | |
| occurrences (all) | 2 | 1 | |
| Reproductive system and breast disorders | | | |

| | | | |
|--|---------------------|---------------------|--|
| Breast pain subjects affected / exposed occurrences (all) | 0 / 58 (0.00%) 0 | 1 / 54 (1.85%) 1 | |
| Ovarian cyst subjects affected / exposed occurrences (all) | 0 / 58 (0.00%) 0 | 1 / 54 (1.85%) 1 | |
| Vaginal haemorrhage subjects affected / exposed occurrences (all) | 0 / 58 (0.00%) 0 | 1 / 54 (1.85%) 1 | |
| Psychiatric disorders Insomnia subjects affected / exposed occurrences (all) | 1 / 58 (1.72%) 1 | 0 / 54 (0.00%) 0 | |
| Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all) | 1 / 58 (1.72%) 1 | 1 / 54 (1.85%) 1 | |
| Aspartate aminotransferase increased subjects affected / exposed occurrences (all) | 1 / 58 (1.72%) 1 | 1 / 54 (1.85%) 1 | |
| Blood creatine phosphokinase increased subjects affected / exposed occurrences (all) | 2 / 58 (3.45%) 2 | 3 / 54 (5.56%) 3 | |
| Body temperature increased subjects affected / exposed occurrences (all) | 0 / 58 (0.00%) 0 | 1 / 54 (1.85%) 1 | |
| C-reactive protein increased subjects affected / exposed occurrences (all) | 1 / 58 (1.72%) 1 | 0 / 54 (0.00%) 0 | |
| Eosinophil count increased subjects affected / exposed occurrences (all) | 1 / 58 (1.72%) 1 | 0 / 54 (0.00%) 0 | |
| Eosinophil percentage increased subjects affected / exposed occurrences (all) | 1 / 58 (1.72%) 1 | 0 / 54 (0.00%) 0 | |
| Haemoglobin abnormal | | | |

| | | | |
|--|----------------|----------------|--|
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Haemoglobin decreased | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 1 / 54 (1.85%) | |
| occurrences (all) | 1 | 1 | |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Lymphocyte count abnormal | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Lymphocyte percentage abnormal | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Mean cell haemoglobin concentration decreased | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 3 / 58 (5.17%) | 2 / 54 (3.70%) | |
| occurrences (all) | 5 | 3 | |
| Platelet count increased | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Protein urine | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| White blood cell count decreased | | | |
| subjects affected / exposed | 2 / 58 (3.45%) | 1 / 54 (1.85%) | |
| occurrences (all) | 2 | 1 | |
| White blood cell count increased | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Injury, poisoning and procedural complications | | | |

| | | | |
|--------------------------------------|-----------------|----------------|--|
| Injury | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Limb injury | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Soft tissue injury | | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) | |
| occurrences (all) | 0 | 1 | |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 2 / 58 (3.45%) | 0 / 54 (0.00%) | |
| occurrences (all) | 8 | 0 | |
| Headache | | | |
| subjects affected / exposed | 6 / 58 (10.34%) | 4 / 54 (7.41%) | |
| occurrences (all) | 8 | 8 | |
| Loss of consciousness | | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) | |
| occurrences (all) | 0 | 1 | |
| Syncope | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 4 / 58 (6.90%) | 2 / 54 (3.70%) | |
| occurrences (all) | 4 | 2 | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Leukopenia | | | |
| subjects affected / exposed | 3 / 58 (5.17%) | 2 / 54 (3.70%) | |
| occurrences (all) | 3 | 3 | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 2 / 58 (3.45%) | 4 / 54 (7.41%) | |
| occurrences (all) | 9 | 4 | |
| Abdominal pain upper | | | |

| | | | |
|-----------------------------|-----------------|----------------|--|
| subjects affected / exposed | 1 / 58 (1.72%) | 3 / 54 (5.56%) | |
| occurrences (all) | 1 | 3 | |
| Anal fissure | | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) | |
| occurrences (all) | 0 | 1 | |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 2 / 54 (3.70%) | |
| occurrences (all) | 0 | 2 | |
| Diarrhoea haemorrhagic | | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) | |
| occurrences (all) | 0 | 1 | |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) | |
| occurrences (all) | 0 | 1 | |
| Frequent bowel movements | | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) | |
| occurrences (all) | 0 | 1 | |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 2 / 54 (3.70%) | |
| occurrences (all) | 0 | 2 | |
| Nausea | | | |
| subjects affected / exposed | 8 / 58 (13.79%) | 1 / 54 (1.85%) | |
| occurrences (all) | 20 | 2 | |
| Proctalgia | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 1 / 54 (1.85%) | |
| occurrences (all) | 1 | 1 | |
| Rectal prolapse | | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) | |
| occurrences (all) | 0 | 1 | |
| Vomiting | | | |
| subjects affected / exposed | 5 / 58 (8.62%) | 1 / 54 (1.85%) | |
| occurrences (all) | 17 | 2 | |
| Hepatobiliary disorders | | | |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |

| | | | |
|---|----------------|----------------|--|
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 2 / 58 (3.45%) | 0 / 54 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Hyperhidrosis | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Onychoclasia | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Rash | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 1 / 54 (1.85%) | |
| occurrences (all) | 1 | 3 | |
| Rash pruritic | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Renal and urinary disorders | | | |
| Leukocyturia | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Pollakiuria | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 2 / 58 (3.45%) | 2 / 54 (3.70%) | |
| occurrences (all) | 9 | 2 | |
| Osteoporosis | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Infections and infestations | | | |
| Bacteriuria | | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) | |
| occurrences (all) | 0 | 1 | |
| Bronchitis | | | |

| | | |
|-----------------------------------|----------------|----------------|
| subjects affected / exposed | 2 / 58 (3.45%) | 0 / 54 (0.00%) |
| occurrences (all) | 2 | 0 |
| Clostridium difficile infection | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) |
| occurrences (all) | 0 | 1 |
| Enterocolitis viral | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) |
| occurrences (all) | 0 | 1 |
| Influenza | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) |
| occurrences (all) | 0 | 1 |
| Lyme disease | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) |
| occurrences (all) | 0 | 1 |
| Nasopharyngitis | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) |
| occurrences (all) | 1 | 0 |
| Pharyngitis | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 1 / 54 (1.85%) |
| occurrences (all) | 1 | 1 |
| Pneumonia | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) |
| occurrences (all) | 0 | 1 |
| Respiratory tract infection | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) |
| occurrences (all) | 1 | 0 |
| Sinusitis | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) |
| occurrences (all) | 0 | 1 |
| Upper respiratory tract infection | | |
| subjects affected / exposed | 3 / 58 (5.17%) | 1 / 54 (1.85%) |
| occurrences (all) | 3 | 1 |
| Urinary tract infection | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 1 / 54 (1.85%) |
| occurrences (all) | 1 | 1 |
| Viral infection | | |

| | | | |
|--|---------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 58 (0.00%) 0 | 1 / 54 (1.85%) 2 | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Hyperkalaemia | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Impaired fasting glucose | | | |
| subjects affected / exposed | 1 / 58 (1.72%) | 0 / 54 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 0 / 58 (0.00%) | 1 / 54 (1.85%) | |
| occurrences (all) | 0 | 1 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported